Essential Hypertension
Conditions
Keywords
Moderate systolic hypertension - adults - aliskiren -ramipril
Brief summary
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
Interventions
150 mg Aliskiren as film-coated tablet
Ramipril 5 mg was given in capsule form.
The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
Sponsors
Study design
Eligibility
Inclusion criteria
* Outpatients \> 18 years * Male or female patients. Female patients must have been either post-menopausal for one year, surgically sterile, or using effective contraceptive methods * Patients with essential hypertension, previously treated with an antihypertensive single-drug therapy, either uncontrolled or intolerant. * BP thresholds at visit 1: * For patients previously treated and uncontrolled: 140≤ office SBP\<180 mmHg * For patients previously treated, controlled but intolerant: office SBP≥130 mmHg * BP thresholds at visit 2 (for all patients): * 160≤office SBP\<180 mmHg AND * 155≤home SBP\<175 mmHg (3-day period of home blood pressure monitoring just before randomization)
Exclusion criteria
* Women of child-bearing potential not using any effective methods of contraception * Severe hypertension (office BP ≥ 180/110 mmHg) * Impossibility to stop abruptly previous antihypertensive treatments at visit 1 * Patients previously untreated or patients treated with two or three antihypertensive medications * History or evidence of a secondary form of hypertension * History of hypersensitivity to ACEi or renin inhibitors * History of heart failure, stroke or coronary heart disease * Serum potassium ≥ 5.2 mmol/l Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) | Baseline to 8 weeks | The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP as covariable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) | Baseline to 8 weeks | The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of variance included treatment factor and baseline value of mean sitting DBP as covariable. |
| Percentage of Patients With Controlled Blood Pressure | At 4 and 8 weeks | The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. Controlled blood pressure (BP) is defined as mean office systolic BP/ diastolic BP \< 140/90 mmHg. |
| Number of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the Night | After 8 weeks | Ambulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the day before visit 4, the device attached to the ambulatory blood pressure non-dominant arm of the patient. The BP morning surge was defined as the average of the measurements taken during the first 2 hours after waking the patient. The minimal night blood pressure was defined as the average of the two lowest BP measures (the lowest hourly average) recorded during night time. |
| Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks) | Baseline to 4 weeks | The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables. |
| Difference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 8 | At week 8 | Ambulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the eve of visit 4 (week 8), the device attached to the ambulatory blood pressure non-dominant arm of the patient. The difference between mean-hour maximum SBP mean-hour minimum SBP between 1 am and 8 am was measured. |
| Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Baseline to 8 weeks | The sub-groups were: Riser = patients with \>= 55 mmHg difference between the mean SPB measured at the morning surge and the mean minimal SBP measured during the night. The Non-risers in whom the difference is \<55 mmHg. Patients called dippers in whom there was a decrease in average nocturnal SBP ≥ 10% compared with average daytime SBP, in contrast to patients non-dippers in whom this difference was \<10%. |
| Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | From 8 weeks to 48 hours after week 8 | The change in blood pressure was measured between visit 4 (end of the period of double-blind active treatment which was at week 8) and visit 5 (48 hours after the last active dose taken) in the group of patients who received aliskiren or placebo and those who received ramipril or placebo. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables. |
| Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III) | 8 weeks + 1 day | Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. |
Countries
France
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ramipril In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
In period III (double-blind withdrawal): At visit 4, patients received placebo or the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4). | 257 |
| Aliskiren In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
In period III (double-blind withdrawal): At visit 4, patients received placebo or the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4). | 249 |
| Total | 506 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Period III (Unblinded,Controlled, 1 Day) | Administrative problems | 0 | 1 | 1 | 1 |
| Period III (Unblinded,Controlled, 1 Day) | Adverse Event | 0 | 0 | 1 | 0 |
| Period III (Unblinded,Controlled, 1 Day) | Protocol Violation | 2 | 0 | 0 | 0 |
| Period III (Unblinded,Controlled, 1 Day) | Withdrawal by Subject | 0 | 0 | 2 | 0 |
| Period II(Randomized,Double Blinded,8wk) | Administrative problems | 2 | 0 | 0 | 0 |
| Period II(Randomized,Double Blinded,8wk) | Adverse Event | 6 | 0 | 5 | 0 |
| Period II(Randomized,Double Blinded,8wk) | Lost to Follow-up | 0 | 0 | 1 | 0 |
| Period II(Randomized,Double Blinded,8wk) | Unsatisfactory therapeutic effect | 1 | 0 | 0 | 0 |
| Period II(Randomized,Double Blinded,8wk) | Withdrawal by Subject | 1 | 0 | 2 | 0 |
Baseline characteristics
| Characteristic | Aliskiren | Ramipril | Total |
|---|---|---|---|
| Age Continuous | 61.0 years STANDARD_DEVIATION 11.4 | 59.8 years STANDARD_DEVIATION 11.6 | 60.4 years STANDARD_DEVIATION 11.5 |
| Age, Customized 50 - 64 years | 115 Participants | 119 Participants | 234 Participants |
| Age, Customized < 50 years | 39 Participants | 56 Participants | 95 Participants |
| Age, Customized 65 - 74 years | 64 Participants | 56 Participants | 120 Participants |
| Age, Customized >= 75 years | 31 Participants | 26 Participants | 57 Participants |
| Sex: Female, Male Female | 133 Participants | 142 Participants | 275 Participants |
| Sex: Female, Male Male | 116 Participants | 115 Participants | 231 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 257 | 0 / 118 | 0 / 248 | 0 / 122 |
| serious Total, serious adverse events | 3 / 257 | 0 / 118 | 1 / 248 | 0 / 122 |
Outcome results
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP as covariable.
Time frame: Baseline to 8 weeks
Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Ramipril | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) | -18.80 mmHg | Standard Error 0.92 |
| Aliskiren | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) | -20.78 mmHg | Standard Error 0.92 |
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of variance included treatment factor and baseline value of mean sitting DBP as covariable.
Time frame: Baseline to 8 weeks
Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with observation at both time points were included in this analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Ramipril | Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) | -5.23 mmHg | Standard Error 0.6 |
| Aliskiren | Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) | -6.39 mmHg | Standard Error 0.6 |
Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)
The sub-groups were: Riser = patients with \>= 55 mmHg difference between the mean SPB measured at the morning surge and the mean minimal SBP measured during the night. The Non-risers in whom the difference is \<55 mmHg. Patients called dippers in whom there was a decrease in average nocturnal SBP ≥ 10% compared with average daytime SBP, in contrast to patients non-dippers in whom this difference was \<10%.
Time frame: Baseline to 8 weeks
Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with observation at different categories were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Risers (n= 3, 9) | -19.7 mmHg | Standard Deviation 6.11 |
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Non-risers (n=109, 103) | -19.2 mmHg | Standard Deviation 13.99 |
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Dippers (n= 80, 94) | -18.1 mmHg | Standard Deviation 11.86 |
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Non-dippers (n= 93, 92) | -19.2 mmHg | Standard Deviation 14.93 |
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Risers (n= 3, 9) | -7.3 mmHg | Standard Deviation 10.6 |
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Non-risers(n=109, 103) | -4.2 mmHg | Standard Deviation 9.51 |
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Dippers (n= 80, 94) | -5.5 mmHg | Standard Deviation 9.63 |
| Ramipril | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Non-dippers (n= 93, 92) | -5.3 mmHg | Standard Deviation 9.59 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Non-dippers (n= 93, 92) | -6.5 mmHg | Standard Deviation 9.56 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Risers (n= 3, 9) | -16.9 mmHg | Standard Deviation 10.52 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Risers (n= 3, 9) | -6.6 mmHg | Standard Deviation 9.11 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Non-risers (n=109, 103) | -20.5 mmHg | Standard Deviation 14.49 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Dippers (n= 80, 94) | -6.3 mmHg | Standard Deviation 9.81 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Dippers (n= 80, 94) | -19.8 mmHg | Standard Deviation 12.05 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msDBP: Non-risers(n=109, 103) | -5.7 mmHg | Standard Deviation 9.61 |
| Aliskiren | Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks) | Change in msSBP: Non-dippers (n= 93, 92) | -21.1 mmHg | Standard Deviation 15.06 |
Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose
The change in blood pressure was measured between visit 4 (end of the period of double-blind active treatment which was at week 8) and visit 5 (48 hours after the last active dose taken) in the group of patients who received aliskiren or placebo and those who received ramipril or placebo. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables.
Time frame: From 8 weeks to 48 hours after week 8
Population: Per-protocol missed dose population included all per protocol population patients who had received the study treatment for period 3 according to the protocol (duration of period 3 and treatment intake). Patients with observation at both time points were included in this analysis.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msSBP | -0.50 mmHg | Standard Error 1.05 |
| Ramipril | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msDBP | 0.76 mmHg | Standard Error 0.69 |
| Aliskiren | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msDBP | 0.32 mmHg | Standard Error 0.79 |
| Aliskiren | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msSBP | -1.28 mmHg | Standard Error 1.1 |
| Aliskiren | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msSBP | 0.52 mmHg | Standard Error 1.06 |
| Aliskiren | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msDBP | -0.40 mmHg | Standard Error 0.78 |
| Placebo to Aliskiren | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msSBP | 3.27 mmHg | Standard Error 1.1 |
| Placebo to Aliskiren | Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose | Change in msDBP | 0.97 mmHg | Standard Error 0.81 |
Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks)
The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables.
Time frame: Baseline to 4 weeks
Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks) | Change in msSBP | -19.42 mmHg | Standard Error 0.92 |
| Ramipril | Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks) | Change in msDBP | -5.37 mmHg | Standard Error 0.56 |
| Aliskiren | Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks) | Change in msSBP | -19.75 mmHg | Standard Error 0.92 |
| Aliskiren | Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks) | Change in msDBP | -5.60 mmHg | Standard Error 0.56 |
Difference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 8
Ambulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the eve of visit 4 (week 8), the device attached to the ambulatory blood pressure non-dominant arm of the patient. The difference between mean-hour maximum SBP mean-hour minimum SBP between 1 am and 8 am was measured.
Time frame: At week 8
Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with ABPM measurements over 24 hours were included in this analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ramipril | Difference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 8 | 33.6 mmHg | Standard Deviation 14.04 |
| Aliskiren | Difference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 8 | 35.5 mmHg | Standard Deviation 15.05 |
Number of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the Night
Ambulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the day before visit 4, the device attached to the ambulatory blood pressure non-dominant arm of the patient. The BP morning surge was defined as the average of the measurements taken during the first 2 hours after waking the patient. The minimal night blood pressure was defined as the average of the two lowest BP measures (the lowest hourly average) recorded during night time.
Time frame: After 8 weeks
Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with ABPM to evaluate the occurrence or absence of a morning peak were included in this analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ramipril | Number of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the Night | 3 Participants |
| Aliskiren | Number of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the Night | 9 Participants |
Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)
Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
Time frame: 8 weeks + 1 day
Population: All randomized patients except one patient from Aliskiren arm who was lost to follow up after visit 2.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ramipril | Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III) | Patients with at least 1 AE | 55 Participants |
| Ramipril | Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III) | Patients with at least 1 SAE | 3 Participants |
| Ramipril | Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III) | Death | 0 Participants |
| Aliskiren | Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III) | Patients with at least 1 AE | 43 Participants |
| Aliskiren | Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III) | Patients with at least 1 SAE | 1 Participants |
| Aliskiren | Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III) | Death | 0 Participants |
Percentage of Patients With Controlled Blood Pressure
The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. Controlled blood pressure (BP) is defined as mean office systolic BP/ diastolic BP \< 140/90 mmHg.
Time frame: At 4 and 8 weeks
Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with observation at each time point were included in this analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ramipril | Percentage of Patients With Controlled Blood Pressure | At week 4 (N= 218, 217) | 36.7 Percentage |
| Ramipril | Percentage of Patients With Controlled Blood Pressure | At week 8 (N= 213, 213) | 26.8 Percentage |
| Aliskiren | Percentage of Patients With Controlled Blood Pressure | At week 4 (N= 218, 217) | 40.1 Percentage |
| Aliskiren | Percentage of Patients With Controlled Blood Pressure | At week 8 (N= 213, 213) | 32.4 Percentage |